La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Statera BioPharma a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Statera BioPharma..

Statera BioPharma (OTC:STAB) Azioni, Catena delle Opzioni

Statera BioPharma

Statera BioPharma Inc is a pre-clinical and clinical biopharmaceutical company developing multiple product candidates to address unmet medical needs for use in diseases involving immune system dysfunction.

STATERA BIOPHARMA INC by Statera Biopharma, Inc.

Statera BioPharma Inc

Stabilis Solutions Inc

Stabilus SE

StableXSwap

Stably USD - True USD

Cabot (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CBT#NYSE">CBT</a>) reported quarterly earnings of $1.90 per share which beat the analyst consensus estimate of $1.85 by 2.7 percent. This is a 6.74 percent increase over earnings of $1.78 per share from the same period last year. The company reported quarterly sales of $936.00 million which missed the analyst consensus estimate of $1.02 billion by 8.61 percent. This is a 8.15 percent decrease over sales of $1.02 billion the same period last year.

Earnings

Earnings Beats

Earnings Misses

News

Cabot Q2 Adj. EPS $1.90 Beats $1.85 Estimate, Sales $936.00M Miss $1.02B Estimate

WIIM

TALO

Talos Energy shares are trading higher after the company reported better-than-expected Q1 financial results.

Tidewater (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDW#NYSE">TDW</a>) reported quarterly earnings of $0.83 per share which beat the analyst consensus estimate of $0.76 by 9.21 percent. This is a 6.74 percent decrease over earnings of $0.89 per share from the same period last year. The company reported quarterly sales of $333.44 million which beat the analyst consensus estimate of $323.60 million by 3.04 percent. This is a 3.82 percent increase over sales of $321.16 million the same period last year.

Tidewater Q1 EPS $0.83 Beats $0.76 Estimate, Sales $333.44M Beat $323.60M Estimate

STRL

Sterling Infrastructure shares are trading higher after the company reported better-than-expected Q1 financial results and raised its FY25 sales guidance.

<h3>GAINERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/XXII">22nd Century Group</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XXII#NASDAQ">XXII</a>) shares closed up 37.31% at $1.40</li>
<li><a href="https://www.benzinga.com/quote/OILFF">Nextleaf Solutions</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/OILFF#OTC">OILFF</a>) shares closed up 15.83% at $0.04</li>
<li><a href="https://www.benzinga.com/quote/TGIFF">1933 Industries</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TGIFF#OTC">TGIFF</a>) shares closed up 15.48% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/CURLF">Curaleaf Holdings</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CURLF#OTC">CURLF</a>) shares closed up 11.46% at $0.93</li>
<li><a href="https://www.benzinga.com/quote/BLOZF">Cannabix Technologies</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BLOZF#OTC">BLOZF</a>) shares closed up 6.98% at $0.44</li>
<li><a href="https://www.benzinga.com/quote/CXXIF">C21 Investments</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CXXIF#OTC">CXXIF</a>) shares closed up 5.47% at $0.16</li>
<li><a href="https://www.benzinga.com/quote/RMHB">Rocky Mountain High</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RMHB#OTC">RMHB</a>) shares closed up 5.17% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/CURR">Currenc Group</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CURR#NASDAQ">CURR</a>) shares closed up 4.15% at $1.36</li>
<li><a href="https://www.benzinga.com/quote/CLSH">CLS Holdings USA</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CLSH#OTC">CLSH</a>) shares closed up 3.55% at $0.04</li>
<li><a href="https://www.benzinga.com/quote/CRON">Cronos Group</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRON#NASDAQ">CRON</a>) shares closed up 3.26% at $1.90</li>
<li><a href="https://www.benzinga.com/quote/SMG">Scotts Miracle Gro</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMG#NYSE">SMG</a>) shares closed up 3.03% at $56.15</li>
</ul>
<h3>LOSERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/MGWFF">Maple Leaf Green World</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/MGWFF#OTC">MGWFF</a>) shares closed down 49.26% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/FUAPF">Global Compliance</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/FUAPF#OTC">FUAPF</a>) shares closed down 28.57% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/BBRRF">Blueberries Medical</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BBRRF#OTC">BBRRF</a>) shares closed down 17.17% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/RSSFF">Affinor Growers</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RSSFF#OTC">RSSFF</a>) shares closed down 15.20% at $0.04</li>
<li><a href="https://www.benzinga.com/quote/LBUY">Leafbuyer Techs</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LBUY#OTC">LBUY</a>) shares closed down 14.58% at $0.02</li>
<li><a href="https://www.benzinga.com/quote/FFNTF">4Front Ventures</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/FFNTF#OTC">FFNTF</a>) shares closed down 12.83% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/CNBX">CNBX Pharmaceuticals</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CNBX#OTC">CNBX</a>) shares closed down 10.00% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/GRWG">GrowGeneration</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRWG#NASDAQ">GRWG</a>) shares closed down 7.20% at $1.16</li>
<li><a href="https://www.benzinga.com/quote/GNLN">Greenlane Hldgs</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNLN#NASDAQ">GNLN</a>) shares closed down 6.86% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/NWVCF">EnWave</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/NWVCF#OTC">NWVCF</a>) shares closed down 6.00% at $0.21</li>
<li><a href="https://www.benzinga.com/quote/MRMD">MariMed</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/MRMD#OTC">MRMD</a>) shares closed down 5.99% at $0.10</li>
<li><a href="https://www.benzinga.com/quote/SOLCF">SOL Global Investments</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SOLCF#OTC">SOLCF</a>) shares closed down 5.32% at $0.09</li>
<li><a href="https://www.benzinga.com/quote/CGC">Canopy Gwth</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGC#NASDAQ">CGC</a>) shares closed down 5.26% at $1.27</li>
<li><a href="https://www.benzinga.com/quote/CRBP">Corbus Pharmaceuticals</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRBP#NASDAQ">CRBP</a>) shares closed down 4.24% at $7.42</li>
<li><a href="https://www.benzinga.com/quote/CBWTF">Auxly Cannabis Group</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CBWTF#OTC">CBWTF</a>) shares closed down 3.85% at $0.06</li>
<li><a href="https://www.benzinga.com/quote/SNDL">SNDL</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDL#NASDAQ">SNDL</a>) shares closed down 3.60% at $1.35</li>
<li><a href="https://www.benzinga.com/quote/LMLLF">Pharmadrug</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LMLLF#OTC">LMLLF</a>) shares closed down 3.03% at $0.01</li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Cannabis

Markets

Movers

BBRRF

BLOZF

CANNABIS WHEATON INCOME by Cannabis Wheaton Income Corp.

CBWTF

CLSH

CNBX

CRBP

CRON

CURALEAF HLDGS INC by Curaleaf Hldgs Inc.

CURLF

CURE PHARMA HLDG CORP by CURE Pharmaceutical Holding Corp.

CURR

CXXIF

FFNTF

FUAPF

GNLN

GRWG

LEAFBUYER TECHNOLOGIES by Leafbuyer Technologies, Inc.

LBUY

LMLLF

MGWFF

MRMD

NWVCF

OILFF

RMHB

RSSFF

SNDL

SOLCF

TGIFF

XXII

Bearish Monday For Marijuana Stocks - Maple Leaf Green World, 22nd Century Group Among Top Gainers

BRC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRCC#NYSE">BRCC</a>) affirms FY2025 sales outlook from $395.00 million-$425.00 million to $395.00 million-$425.00 million vs $406.50 million estimate.

Guidance

BRCC

BRC Affirms FY2025 Sales Guidance of $395.00M-$425.00M vs $406.50M Est

Upwork, Inc.&nbsp; (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPWK#NASDAQ">UPWK</a>) released its first-quarter results after Monday's closing bell. Here's a look at the <a href="https://www.benzinga.com/pressreleases/25/05/g45206225/upwork-reports-first-quarter-2025-financial-results">details from the report.&nbsp;</a>
The Details:&nbsp;Upwork reported quarterly earnings of&nbsp;34&nbsp;cents per share which beat the analyst consensus estimate of&nbsp;26&nbsp;cents. Quarterly revenue came in at $192.71 million,&nbsp;which beat the analyst consensus estimate of&nbsp;$188.32 million and is up from revenue of&nbsp;$190.94 million&nbsp;from the same period last year.
Read Next: <a href="https://www.benzinga.com/news/earnings/25/05/45194998/saudi-arabias-oil-power-play-jolts-markets-can-diamondback-and-rivals-survive-the-squeeze?utm_source=articleShare">Saudi Arabia&#8217;s Oil Power Play Jolts Markets: Can Diamondback And Rivals Survive The Squeeze?</a>
The company reported 812,000 active clients and GSV per active client&nbsp;of $4,912, which increased 3% year-over-year, reflecting positive growth for the first time in six quarters.
&#8220;Upwork is off to a strong start in 2025, delivering record first-quarter results across revenue and profitability, a testament to the team&#8217;s accelerated execution and the resilience of our business model,&#8221; said Hayden Brown, CEO of Upwork. 
&#8220;We are incredibly excited by the early impact of our strategic product investments in AI, which are already enhancing customer productivity and engagement. With positive momentum across our business and a winning strategy for AI innovation, we are confident in our path to expand market share, drive ongoing profitability, and continue to be the category leader at the intersection of talent, technology and work,&#8221; Brown added.
Outlook:&nbsp;Upwork raised its fiscal 2025 adjusted earnings per share guidance from a range of $1.05 to $1.10&nbsp;to&nbsp;a range of $1.14 to $1.18, versus the&nbsp;$1.07&nbsp;analyst estimate. The company affirmed its fiscal year revenue guidance of $740 million to $760 million, versus the&nbsp;$750.22 million&nbsp;estimate.
UPWK Price Action: According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Upwork stock was up 11.49% after hours at $14.85 on Monday.&nbsp;&nbsp;
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/news/management/25/05/45180224/these-ev-makers-could-shine-if-musk-leaves-tesla?utm_source=articleShare">These EV Makers Could Shine If Musk Leaves Tesla</a></li>
</ul>
Image: Shutterstock

After-Hours Center

UPWK

Upwork Stock Rallies After Better-Than-Expected Q1, Raised FY25 EPS Guidance

BFAM

Bright Horizons Family Q1 Adj. EPS $0.77 Beats $0.64 Estimate, Sales $665.53M Miss $665.65M Estimate

Crescent Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRGY#NYSE">CRGY</a>) reported quarterly earnings of $0.56 per share which beat the analyst consensus estimate of $0.46 by 21.74 percent. This is a 21.74 percent increase over earnings of $0.46 per share from the same period last year. The company reported quarterly sales of $950.17 million which beat the analyst consensus estimate of $944.92 million by 0.56 percent. This is a 44.52 percent increase over sales of $657.47 million the same period last year.

CRGY

Crescent Energy Q1 Adj. EPS $0.56 Beats $0.46 Estimate, Sales $950.17M Beat $944.92M Estimate

Biomea Fusion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMEA#NASDAQ">BMEA</a>) reported quarterly losses of $(0.80) per share which missed the analyst consensus estimate of $(0.61) by 31.15 percent. This is a 26.61 percent increase over losses of $(1.09) per share from the same period last year.

BMEA

Biomea Fusion Q1 EPS $(0.80) Misses $(0.61) Estimate

AMRC

Ameresco shares are trading higher after the company reported better-than-expected Q1 financial results and issued FY25 guidance with its midpoint above estimates.

BRC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRCC#NYSE">BRCC</a>) reported quarterly losses of $(0.04) per share which missed the analyst consensus estimate of $(0.03) by 33.33 percent. This is a 500 percent decrease over earnings of $0.01 per share from the same period last year. The company reported quarterly sales of $89.97 million which beat the analyst consensus estimate of $88.09 million by 2.14 percent. This is a 8.56 percent decrease over sales of $98.39 million the same period last year.

BRC Q1 EPS $(0.04) Misses $(0.03) Estimate, Sales $89.97M Beat $88.09M Estimate

The new Senior Leadership appointments will be effective immediately and include:
<ul>
<li>Amy Montagne, previously VP/GM Global Women's, has been promoted to President, Nike, responsible for obsessing and serving consumers across all sports and driving future growth for the Nike Brand.</li>
<li>Phil McCartney, formerly VP, Footwear, has been promoted to EVP, Chief Innovation, Design &amp; Product Officer responsible for the creation of innovative and coveted product, season-after-season. This includes how Nike, Jordan and Converse innovates, designs, and creates products for athletes around the world.</li>
<li>Nicole Graham, previously Chief Marketing Officer, has been promoted to EVP, Chief Marketing Officer, leading Nike, Jordan and Converse storytelling to inspire consumers and shape the brands for distinction through the passion and emotion of sport.</li>
<li>Tom Clarke, currently strategic advisor to the CEO and member of the SLT, has assumed the new role of Chief Growth Initiatives Officer.</li>
</ul>

Management

Nike Appoints Amy Montagne Has Been Promoted To President, Effective Immediately

<ul>
<li>President and CEO Alan Armstrong to become Executive Chairman, effective July 1, 2025</li>
<li>Executive Vice President Chad Zamarin named President and CEO, effective July 1, 2025</li>
</ul>
Williams (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMB#NYSE">WMB</a>) today announced that effective July 1, 2025, President and CEO Alan Armstrong will become executive chairman of the Williams Board of Directors and Chad Zamarin, currently executive vice president of Corporate Strategic Development, will succeed him as president and CEO and will join the Williams board. Stephen Bergstrom, current chairman of the board, will transition to lead independent director.

Williams Names Chad Zamarin To Succeed Alan Armstrong As CEO, Effective July 1, 2025; Alan Armstrong to Become Executive Chairman

Fabrinet shares are trading lower after the company reported a Q3 adjusted EPS miss and issued Q4 guidance with its midpoint below estimates.

Offerpad Solutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OPAD#NYSE">OPAD</a>) sees Q2 sales of $160.000 million-$190.000 million vs $265.83 million analyst estimate.

OPAD

Offerpad Solutions Sees Q2 Sales $160.000M-$190.000M vs $265.83M Est

EDUC

Educational Development Corporation Announces New Fiscal Year 2025 Earnings Call Date On May 19, 2025

Offerpad Solutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OPAD#NYSE">OPAD</a>) reported quarterly losses of $(0.55) per share which missed the analyst consensus estimate of $(0.50) by 10 percent. This is a 15.38 percent increase over losses of $(0.65) per share from the same period last year. The company reported quarterly sales of $160.70 million which missed the analyst consensus estimate of $274.48 million by 41.45 percent. This is a 43.68 percent decrease over sales of $285.36 million the same period last year.

Offerpad Solutions Q1 EPS $(0.55) Misses $(0.50) Estimate, Sales $160.70M Miss $274.48M Estimate

Primoris Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRIM#NYSE">PRIM</a>) affirms FY2025 GAAP EPS guidance from $3.70-$3.90 to $3.70-$3.90..

PRIM

Primoris Services Affirms FY2025 GAAP EPS Guidance of $3.70-$3.90

BofA Securities analyst Justin Post reiterated a Buy rating on the shares of Expedia Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXPE#NASDAQ">EXPE</a>) on Monday and lowered the price forecast from $250.00 to $205.00.
The analyst expects Expedia to face challenges from a slowdown in U.S. travel demand ahead of its May 8 earnings report.
With peers reporting weaker year-over-year growth in booked nights and domestic air travel showing signs of pressure, Expedia's nights growth is projected to slow to 5% in the first quarter.
Bookings are estimated at $31.5 billion, slightly below consensus. The second-quarter EBITDA is forecast at $272 million, which is helped by Trivago revenue and lower first-quarter marketing costs.
U.S. travel indicators are softening, with TSA enplanements nearly flat in March and hotel revenue per available room (RevPAR) turning negative in April. 
Also Read: <a href="https://www.benzinga.com/25/05/45175845/wall-street-reacts-as-airbnb-eyes-growth-amid-us-slowdown-details">Wall Street Reacts As Airbnb Eyes Growth Amid US Slowdown</a>
Both Booking and Airbnb have forecast slower quarter-over-quarter growth in the second quarter nights.
Expedia aims to protect margins by cutting about 3% of its workforce in April, following earlier reductions. This signals continued focus on year-over-year margin improvement.
Post trimmed his 2025 estimates for Expedia, projecting just 3% growth in bookings and 4% in revenue, with B2C expected to decline slightly.
Second-quarter nights and bookings growth are now at 2% year-over-year, marking a slowdown. EBITDA forecasts for 2025 and 2026 are reduced to $3.1 billion and $3.3 billion, respectively.
According to Post, the cut in the price forecast reflects trimmed estimates and sector-wide valuation compression. Despite this, the analyst maintained a &#8220;Buy&#8221; rating, citing the stock's attractive valuation at just 7x projected 2026 free cash flow and 6x EBITDA.
He said improved execution under Expedia's new management and a rebound in U.S. travel trends could help narrow the valuation gap with Booking Holdings.
Price Action: EXPE shares traded higher by 2.24% at $165.41 at last check Monday.
Read Next: <a href="https://www.benzinga.com/25/05/45194848/footwear-giant-skechers-to-go-private-in-more-than-9b-deal-with-3g-capital-stock-surges">Footwear Giant Skechers To Go Private At 30% Premium In PE Deal</a>
Photo: Shutterstock

Price Target

Reiteration

Analyst Ratings

General

EXPE

Expedia Faces Turbulence As US Travel Trend Weakens, Says BofA Analyst

Press Releases

Tivic Health Acquires Exclusive Worldwide Rights to Phase III TLR5 Agonist from Statera Biopharma

STAB

TIVC

Comments

Statera BioPharma

Statera BioPharma (STAB) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO